Sarepta Therapeutics, Inc.-Product Pipeline Review-2015

Sarepta Therapeutics, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07170CDB
  • |
  • Pages: 68
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Sarepta Therapeutics, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Sarepta Therapeutics, Inc.-Product Pipeline Review-2015', provides an overview of the Sarepta Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Sarepta Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Sarepta Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Sarepta Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Sarepta Therapeutics, Inc.'s pipeline products

Reasons To Buy

Evaluate Sarepta Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Sarepta Therapeutics, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Sarepta Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Sarepta Therapeutics, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sarepta Therapeutics, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Sarepta Therapeutics, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Sarepta Therapeutics, Inc. Snapshot 7

Sarepta Therapeutics, Inc. Overview 7

Key Information 7

Key Facts 7

Sarepta Therapeutics, Inc.-Research and Development Overview 8

Key Therapeutic Areas 8

Sarepta Therapeutics, Inc.-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Sarepta Therapeutics, Inc.-Pipeline Products Glance 13

Sarepta Therapeutics, Inc.-Late Stage Pipeline Products 13

Phase III Products/Combination Treatment Modalities 13

Sarepta Therapeutics, Inc.-Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

Sarepta Therapeutics, Inc.-Early Stage Pipeline Products 15

IND/CTA Filed Products/Combination Treatment Modalities 15

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

Sarepta Therapeutics, Inc.-Drug Profiles 18

eteplirsen 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

SRP-4053 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

AVI-7288 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

radavirsen 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

SRP-4045 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

PMO-25 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

SRP-4044 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

SRP-4050 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

SRP-4052 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Antisense Oligonucleotide for Acinetobacter baumannii Infections 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Antisense Oligonucleotide for Rare Disease 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Antisense Oligonucleotide to Activate Lamin A for Progeria 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Antisense Oligonucleotides for Infectious Diseases 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Bacterial PPMO 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

SRP-4008 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

SRP-4055 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Viral PMO-X 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Sarepta Therapeutics, Inc.-Pipeline Analysis 46

Sarepta Therapeutics, Inc.-Pipeline Products by Target 46

Sarepta Therapeutics, Inc.-Pipeline Products by Route of Administration 47

Sarepta Therapeutics, Inc.-Pipeline Products by Molecule Type 48

Sarepta Therapeutics, Inc.-Pipeline Products by Mechanism of Action 49

Sarepta Therapeutics, Inc.-Recent Pipeline Updates 50

Sarepta Therapeutics, Inc.-Dormant Projects 61

Sarepta Therapeutics, Inc.-Discontinued Pipeline Products 62

Discontinued Pipeline Product Profiles 62

AVI-4065 62

AVI-6002 62

AVI-7537 62

Sarepta Therapeutics, Inc.-Company Statement 63

Sarepta Therapeutics, Inc.-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Appendix 67

Methodology 67

Coverage 67

Secondary Research 67

Primary Research 67

Expert Panel Validation 67

Contact Us 67

Disclaimer 68

List of Tables

Sarepta Therapeutics, Inc., Key Information 7

Sarepta Therapeutics, Inc., Key Facts 7

Sarepta Therapeutics, Inc.-Pipeline by Indication, 2015 9

Sarepta Therapeutics, Inc.-Pipeline by Stage of Development, 2015 11

Sarepta Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 12

Sarepta Therapeutics, Inc.-Phase III, 2015 13

Sarepta Therapeutics, Inc.-Phase I, 2015 14

Sarepta Therapeutics, Inc.-IND/CTA Filed, 2015 15

Sarepta Therapeutics, Inc.-Preclinical, 2015 16

Sarepta Therapeutics, Inc.-Discovery, 2015 17

Sarepta Therapeutics, Inc.-Pipeline by Target, 2015 46

Sarepta Therapeutics, Inc.-Pipeline by Route of Administration, 2015 47

Sarepta Therapeutics, Inc.-Pipeline by Molecule Type, 2015 48

Sarepta Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2015 49

Sarepta Therapeutics, Inc.-Recent Pipeline Updates, 2015 50

Sarepta Therapeutics, Inc.-Dormant Developmental Projects,2015 61

Sarepta Therapeutics, Inc.-Discontinued Pipeline Products, 2015 62

Sarepta Therapeutics, Inc., Other Locations 66

Sarepta Therapeutics, Inc., Subsidiaries 66

List of Figures

Sarepta Therapeutics, Inc.-Pipeline by Top 10 Indication, 2015 9

Sarepta Therapeutics, Inc.-Pipeline by Stage of Development, 2015 11

Sarepta Therapeutics, Inc.-Monotherapy Products in Pipeline, 2015 12

Sarepta Therapeutics, Inc.-Pipeline by Top 10 Target, 2015 46

Sarepta Therapeutics, Inc.-Pipeline by Top 10 Route of Administration, 2015 47

Sarepta Therapeutics, Inc.-Pipeline by Top 10 Molecule Type, 2015 48

Sarepta Therapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Sarepta Therapeutics, Inc.; Sarepta Therapeutics, Inc. - Key Therapeutics; Sarepta Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Sarepta Therapeutics, Inc. - News; Sarepta Therapeutics, Inc. - Latest Updates; Sarepta Therapeutics, Inc. - Pipeline; Sarepta Therapeutics, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102450
Site License
USD 3000 INR 204900
Corporate User License
USD 4500 INR 307350



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]